Fundamental Immunology & Its Therapeutic Potential
April 25 - 29, 2017
Abstract Deadline: February 20, 2017
Eric Pamer, Memorial Sloan Kettering Cancer Center
Fiona Powrie, University of Oxford, UK
Stephen Smale, UCLA School of Medicine
We are pleased to announce the 2nd Cold Spring Harbor meeting on Fundamental Immunology & Its Therapeutic Potential, which will begin on Tuesday evening, April 25 and end at noon on Saturday, April 29, 2017. The meeting will have a unique focus aimed at enhancing fundamental immunology research while speeding the translation of basic immunology discoveries to the clinic.
The immunology field has entered an exciting new era in which our expanding knowledge of immune regulation is leading to innovative new therapies for the treatment of cancer, infectious diseases, autoimmune and inflammatory disorders, and other diseases. Future clinical advances will continue to be driven by fundamental discoveries, highlighting the importance of strong interactions between basic and translational researchers. Furthermore, it has been firmly established that research advances originally made while studying one type of disease can lead to important therapeutic advances in another disease. One striking example is the remarkable success of checkpoint blockage therapies for the treatment of cancer, drawing on initial fundamental studies in infectious disease models.
With these issues in mind, the objective of this new meeting will be to bring leading senior and junior investigators working on fundamental questions in immunology together with an equally strong group of researchers who have had experience and success translating fundamental advances to the clinic. The meeting will also promote interactions between researchers working on diverse diseases, by including cancer, infectious diseases, autoimmunity and other relevant diseases
- Fundamental Immunology
- Vaccines and Anti-Viral Immunity
- Anti-tumor Immunity
- T-Regulatory Cells
- Tumor Microenvironment and ILCs
- Metabolism and Microbiota
- Microbiota and NK Cells
- T-Cell Differentiation and Anti-Microbial Immunity
Nicholas Arpaia, Columbia University
David Artis, Weill Cornell Medical College, Cornell University
Rosa Bacchetta, Stanford University School of Medicine
Aimee Beaulieu, Rutgers University, New Jersey Medical School
Yasmine Belkaid, National Institute of Allergy & Infectious Diseases
Pamela Bjorkman, California Institute of Technology/HHMI
Jeffrey Bluestone, University of California, San Francisco
Igor Brodsky, University of Pennsylvania
Mark Davis, HHMI, Stanford University School of Medicine
Thomas Gajewski, University of Chicago, Medical School
Jane Grogan, Genentech
Nir Hacohen, Massachusetts General Hospital & Broad Institute
Timothy Hand, University of Pittsburgh
Kenya Honda, Keio University School of Medicine, Japan
Sun Hur, Harvard Medical School
Susan Kaech, HHMI/Yale University School of Medicine
Michael Karin, University of California, San Diego
Lewis Lanier, University of California, San Francisco
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Ming Li, Memorial Sloan-Kettering Cancer Center
Michel Nussenzweig, HHMI/Rockefeller University
Erika Pearce, Max Planck Institute, Germany
David Raulet, University of California, Berkeley
Alexander Rudensky, Memorial Sloan Kettering Cancer Center
Michel Sadelain, Memorial Sloan Kettering Cancer Center
Shomyseh Sanjabi, University of California San Francisco
Peter Savage, University of Chicago
Andrea Schietinger, Memorial Sloan Kettering Cancer Center
Harinder Singh, Cincinnati Children's Hospital Medical Center
Gregory Sonnenberg, Weill Cornell Medical College
Jakob von Moltke, University of Washington
E. John Wherry, University of Pennsylvania Medical School
Lili Yang, University of California, Los Angeles
Cassian Yee, UT MD Anderson Cancer Center
Liang Zhou, University of Florida
The format of the meeting will include eight oral sessions and two poster sessions. Each oral session will include invited speakers and speakers selected from submitted abstracts. For this reason, abstracts from both junior and senior investigators are warmly invited. The abstracts should focus on new and unpublished data. The status (talk/poster) of abstracts will be posted on our web site (below) as soon as decisions have been made by the organizers.
We have applied for funds from government and industry to partially support graduate students and postdocs. Any questions about registration, abstract submission, or financial assistance should be directed to Val Pakaluk.
The designated hashtag for this meeting is #cshlimmtx. Note that you must obtain permission from an individual presenter before live-tweeting or discussing his/her talk, poster, or research results on social media. Click the Policies tab above to see our full Confidentiality & Reporting Policy.
We look forward to seeing you at Cold Spring Harbor in April.
This conference is supported in part by AbbVie and Genentech.
Academic Package $1,455
Graduate/PhD Student Package $1,210
Corporate Package $1,865
Academic/Student No-Housing Package $985
Corporate No-Housing Package $1,250
Regular packages are all-inclusive and cover registration, food, housing, parking, a wine-and-cheese party, cocktail reception, and lobster banquet. No-Housing packages include all costs except housing. Full payment is due four weeks prior to the meeting.